Join the Global Breast Cancer Movement
Save this page to myKomen
Go to myKomen
Home > Understanding Breast Cancer > Treatment > Treatment References

  


Treatment References

Loading...

Treatment References

  1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 110(10):2119-52, 2007.
  2. Goel MS, Burns RB, Phillips RS, Davis RB, Ngo-Metzger Q, McCarthy EP. Trends in breast conserving surgery among Asian Americans and Pacific Islanders, 1992-2000. J Gen Intern Med. 20(7):604-11, 2005.
  3. American Cancer Society. Detail guide: Surgery for breast cancer. http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Surgery_5.asp?sitearea=, 2007.
  4. Chagpar AB, Studts JL, Scoggins CR, et al. for the University of Louisville Breast Sentinel Lymph Node Study. Factors associated with surgical options for breast carcinoma. Cancer. 106(7):1462-6, 2006.
  5. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 86: 628-37, 1999.
  6. National Cancer Institute. Radiation therapy and you: support for people with cancer. http://www.cancer.gov/cancertopics/radiation-therapy-and-you, 2007.
  7. Kirova YM, De Rycke Y, Gambotti L, Pierga J-Y, Asselain B, Fourquet A for the Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 98(5):870-4, 2008.
  8. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 97(6):1404-11, 2003.
  9. Roychoudhuri R, Evans H. Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 91(5):868-72, 2004.
  10. Shelley W, Brundage M, Hayter C, et al. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 47: 1219-28, 2000.
  11. Schomberg PJ, Shanahan TG, Ingle JN, et al. Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study. Radiology. 202: 565-9, 1997.
  12. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 94: 1143-50, 2002.
  13. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trial. Lancet. 366(9503):2087-2106, 2005.
  14. Antonucci JV, Wallace M, Goldstein NS, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys. 74(2):447-52, 2009.
  15. Benitez PR, Keisch ME, Vicini F, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 194(4):456-62, 2007.
  16. National Cancer Institute. Chemotherapy and you: support for people with cancer. http://www.nci.nih.gov/cancertopics/chemotherapy-and-you/page7#SE7, 2007.
  17. Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 21:55-64, 2004.
  18. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women's healthy eating and living (WHEL) study. Breast Cancer Res Treat. 105(2):177-86, 2007.
  19. Goodwin PJ, Ennis ME, Pritchard KI, et al. Adjuvant treatment and onset of menopause predicts weight gain after breast cancer diagnosis. J Clin Oncol. 17(1):120-9, 1999.
  20. Lyman GH, Kuderer NM. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. Clin Breast Cancer. 7(5):372-9, 2006.
  21. Paik S, Shak S, Tang G, et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med, 2004.
  22. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 299(13):1574-87, 2008.
  23. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101(1):113-21, 2007.
  24. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9(1):R7, 2007.
  25. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 302(13):1429-36, 2009.
  26. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 3:CD003474, 2005.
  27. Hillner BE, Ingle JN, Chlebowski RT, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 21(21):4042-57, 2003.
  28. Gnant M, Mlineritsch B, Schippinger W, et al. for the ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 360(7):679-91, 2009.
  29. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19(3):420-32, 2008.
  30. Wardle A. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist. 11 Suppl 1:20-6, 2006.
  31. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 342: 1069-76, 2000.
  32. Roche’ H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: The French PEGASE Experience. Cancer Control. 10:42-48, 2003.
  33. Farquhar C, Marjoribanks J, Basser R et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer (Review). The Cochrane Database Syst Rev. 3:CD003142.pub2, 2005.
  34. Kröger N, Frick M, Gluz O, et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol. 24(24):3919-26, 2006.
  35. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 26(1):37-43, 2008.
  36. Murphy B and Muss HB. Hormonal therapy of breast cancer: state of the art. Oncology (Huntingt). 11: 7-13, 1997.
  37. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 18 Suppl 8:viii26-35, 2007.
  38. National Cancer Institute. Tamoxifen. http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen, 2008.
  39. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 97(22):1652-62, 2005.
  40. Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. (4):CD004562, 2008.
  41. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol, 2004.
  42. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350: 1081-92, 2004.
  43. Jakesz R, Jonat W, Gnant M, et al. on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and the German Adjuvant Breast Cancer Group (GABG). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 366(9484):455-62, 2005.
  44. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. for the BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 361(8):766-76, 2009.
  45. Coombes RC, Kilburn LS, Snowdon CF, et al. for the Intergroup Exemestane Study (IES). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369(9561):559-70, 2007.
  46. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 25(19):2664-70, 2007.
  47. Forbes JF, Cuzick J, Budzar A, Howell A, Tobias JS, Baum M for the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9(1):45-53, 2008.
  48. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 26(12):1948-55, 2008.
  49. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 25(36):5715-22, 2007.
  50. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 26(7):1051-7, 2008.
  51. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 19(8):1407-16, 2008
  52. U.S. Food and Drug Administration. Information on Bisphosphonates. http://www.fda.gov/cder/drug/infopage/bisphosphonates/default.htm, 2008.
  53. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353(16):1673-84, 2005.
  54. Smith I, Procter M, Gelber RD, et al. for the Herceptin Adjuvant (HERA) study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555):29-36, 2007.
  55. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 13(6):620-30, 2008.
  56. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 295(21):24922502, 2006.
  57. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 18(12):1927-34, 2007.
  58. Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 94(10):1189-1200, 2007.
  59. Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J. 13(3):243-50, 2007.
  60. Waljee JF, Newman LA. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin North Am. 87(2):399-415, 2007.
  61. Morrow M and Harris JR. Chapter 33: Ductal carcinoma in situ and microinvasive carcinoma, in Harris JR LM, Morrow M, Osborne CK. Diseases of the Breast, Lippincott Williams and Wilkins, 2004.
  62. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J. 12(1):20-7, 2006.
  63. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.1.200p. http://www.nccn.org, 2009.
  64. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 28(4):400-18, 2001.
  65. Houghton J, George WD, Cuzick J, et al. for the UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) Working Party on behalf of DCIS Trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 362(9378):95-102, 2003.
  66. Leonard GD and Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 96: 906-20, 2004.
  67. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 8(9):1377-85, 2008.
  68. Boyages J, Delaney G and Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 85: 616-28, 1999.
  69. American College of Radiology. Practice guideline for the management of ductal carcinoma in-situ of the breast (DCIS). J Am Coll Surg. 205(1):145-161, 2007.
  70. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. (1):CD000563, 2009.
  71. Vogel VG, Constantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 295(23):2727-41, 2006.
  72. Wickerham DL, Costantino JP, Vogel VG, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res. 181:113-9, 2009.
  73. National Cancer Data Base, Commission on Cancer, American College of Surgeons. Five year survival table for breast cancer cases diagnosed in 1998 and 1999: All states/data reported from 1247 hospitals. National Cancer Data Base website: http://cromwell.facs.org/BMarks/BMPub/ver9/Surv/BMPub_Surv9.cfm, 2008.
  74. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 23(16):3676-85, 2005.
  75. Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol. 66(1):31-41, 2008.
  76. Yang R, Cheung MC, Hurley J, et al. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat. 2009 Jan 24. [Epub ahead of print].
  77. Hortobagyi GN, Singletary SE, Strom EA. Locally Advanced Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, third edition. Philadelphia: Lippincott Williams & Wilkins, 2004.
  78. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 55(5):1200-8, 2003.
  79. Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 22:9-23, 2005-2006.
  80. American Cancer Society. Breast Cancer Cancer Facts & Figures 2009-2010, 2009.
  81. Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat. 80 Suppl 1:S19-26, 2003.
  82. Wood WC, Muss HB, Solin LJ, Olopade OI. Malignant tumors of the breast, in Devita VT Jr, Hellman S, Rosenberg SA. Cancer: Principals and Practice of Oncology, 7th edition. Philadelphia:,Lippincott Williams & Wilkins,2005.
  83. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17: 2639-48, 1999.
  84. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783-92, 2001.
  85. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20(3):719-26, 2002.
  86. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22(6):1063-70, 2004.
  87. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-postive advanced breast cancer. J Natl Cancer Inst. 96(10):759-69, 2004.
  88. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 24(18):2786-92, 2006.
  89. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 110(5):965-72, 2007.
  90. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26(10):1642-9, 2008.
  91. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733-43, 2006.
  92. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357(26):2666-76, 2007.
  93. U.S. Food and Drug Administration. New approval for bevacizumab (Avastin). http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802.htm, 2008.
  94. National Cancer Institute. Eating Hints for Cancer Patients: Before, During, and After Treatment. http://www.cancer.gov/cancertopics/eatinghints/page3#C3, 2009.
  95. Jones M, Schenkel B, Just J, Fallowfield L. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer. 101(8):1720-32, 2004.
  96. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 26(1):132-49, 2008.
  97. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 8(2):R13, 2006.
  98. Adamo V, Iorfida M, Montalto E, et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol. 18 Suppl 6:vi53-7, 2007.
  99. Fine NA and Mustoe TA. Chapter 46: Breast reconstruction, in Harris JR LM, Morrow M, Osborne CK. Diseases of the Breast, Lippincott Williams and Wilkins, 2004.
  100. American Society of Plastic Surgeons. Breast reconstruction following breast removal. http://www.plasticsurgery.org/public_education/procedures/BreastReconstruction.cfm?RenderForPrint=1, 2009.
  101. Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg. 55(3):232-9, 2005.
  102. Gamboa-Bobadilla GM. Implant breast reconstruction using acellular dermal matrix. Ann Plast Surg. 56(1):22-5, 2006.
  103. United States Food and Drug Administration (FDA). Breast implants. http://www.fda.gov/cdrh/breastimplants/index.html, 2006.
  104. American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons. Breast implant safety. http://www.breastimplantsafety.org, 2009.
  105. The University of Texas MD Anderson Cancer Center. Breast reconstruction guide for patients. http://www.mdanderson.org/Diseases/BreastCancer/reconstruction/, 2009.
  106. Granzow JW, Levine JL, Chiu ES, Allen RJ. Breast reconstruction using perforator flaps. Breast reconstruction using perforator flaps. J Surg Oncol. 94(6):441-54, 2006.
  107. Cunnick GH, Mokbel K. Skin-sparing mastectomy. Am J Surg. 188(1):78-84, 2004.
  108. Greenway RM, Schlossberg L, Dooley WC. Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer. Am J Surg. 190(6):918-22, 2005.
  109. Benediktsson KP, Perbeck L. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol. 34(2):143-8, 2008.
  110. Petit JY, Veronesi U, Rey P, et al. Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases. Breast Cancer Res Treat. 114(1):97-101, 2009.
  111. Crowe JP, Patrick RJ, Yetman RJ, Djohan R. Nipple-sparing mastectomy update: one hundred forty-nine procedures and clinical outcomes. Arch Surg. 143(11):1106-10, 2008.
  112. American Cancer Society. Breast reconstruction after mastectomy. http://www.cancer.org/docroot/CRI/content/CRI_2_6X_Breast_Reconstruction_After_Mastectomy_5.asp, 2007.
  113. National Cancer Institute. Breast cancer treatment and pregnancy. http://www.cancer.gov/cancertopics/pdq/treatment/breast-cancer-and-pregnancy/patient, 2008.
  114. Dickson RB, Pestell RJ, Lippman ME. Cancer of the Breast, in Devita VT Jr, Hellman S, Rosenberg SA. Cancer: Principals and Practice of Oncology, 7th edition. Philadelphia:,Lippincott Williams & Wilkins,2005.
  115. Loibl S, von Minckwitz G, Gwyn K. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 106(2):237-46, 2006.
  116. Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 19(4):607-13, 2008.
  117. Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 30:44-51, 2001.
  118. Agrawal A, Ayantunde AA, Rampaul R, Robertson JFR. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 103(1):11-21, 2007.
  119. American Cancer Society. Making Treatment Decisions: Clinical trials-what you need to know. http://our.cancer.org/docroot/ETO/content/ETO_6_3_Clinical_Trials_-_Patient_Participation.asp, 2008.
  120. National Cancer Institute. Participating in a Trial: Questions to ask your doctor. http://www.cancer.gov/clinicaltrials/learning/questions-to-ask-about-participating, 2008.
  121. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 7(9):1225-41, 2007.
  122. Cherny NI and Olsha O. Chapter 76: Brachial plexopathy in patients with breast cancer, in Harris JR LM, Morrow M, Osborne CK. Diseases of the Breast, Lippincott Williams and Wilkins, 2004.
  123. Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P for the Ontario Clinical Oncology Group.The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical Oncology Group. Cancer. 88(10):2260-6, 2000.
  124. World Health Organization (WHO). Cancer Pain Relief, second edition. Geneva: WHO, 1996.
  125. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.1.2009. http://www.nccn.org/, 2009.
  126. American Cancer Society. Pain control: A guide for people with cancer and their families. . http://www.cancer.org/docroot/MIT/content/MIT_7_2x_Pain_Control_A_Guide_for_People_with_Cancer_and_Their_Families.asp, 2008. 
  127. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/cancertopics/paincontrol/allpages, 2008.
  128. McCaffrey M and Pasero C. Pain clinical manual, second edition. New York, NY: Mosby, 1999.
  129. Portenoy RK. Contemporary Diagnosis and Management of Pain in Oncologic and AIDS Patients, third edition. Newton, PA: Handbooks in Health Care Company, 2000.
  130. Fong PC, Boss DS, Yap TA, et al. N Engl J Med. 361(2):123-34, 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Getting Good Care References

1. Weeks J. Breast cancer management: developing a patient sourcebook. Boston, Harvard Center for Cancer Prevention Workshop, 1998.

2. Roohan PJ, Bickell NA, Baptiste MS, et al. Hospital volume differences and five-year survival from breast cancer. Am J Public Health. 88: 454-7, 1998.

3. Hillner BE, Smith TJ and Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 18: 2327-40, 2000.

4. Skinner KA, Helsper JT, Deapen D, et al. Breast cancer: Do specialists make a difference? Ann Surg Oncol. 10(6):606-15, 2003.

5. Gilligan MA, Neuner J, Zhang X, Sparapani R, Laud PW, Nattinger AB. Relationship between number of breast cancer operations performed and 5-year survival after treatment for early-stage breast cancer. Am J Public Health. 97(3):539-44, 2007.

Updated 10/19/09

 

 

Related Links

Visited by Others

Komen Videos